Frank Kondrad

Frank Kondrad is a seasoned business leader with 44 years of global pharmaceutical industry experience. As Senior Vice President of Corporate Development and Licensing (consultant) for Epizon Pharma and Managing Partner of Kondrad Consulting Group, LLC, Frank brings a wealth of expertise in various areas including business development, drug development strategy, commercial brand and payer marketing, pricing research, primary market research, and strategic planning. During his tenure as Vice President of Corporate and Business Development (consultant) for NeuroBo Pharmaceuticals, Frank led the in-licensing efforts for both a new novel dual oxyntomodulin (OXM) analog agonist product, functioning as a GLP-1R and glucagon receptor dual agonist for obesity, and a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for diabetes. During his tenure as Head of Project Management (consultant) for Shackelford Pharma, Frank spearheaded the R&D Team’s efforts to develop a novel new drug product aimed at treating severe epilepsy. Frank holds a degree with honors from Philadelphia College of Pharmacy & Science and has completed graduate programs in pharmacology, business, and leadership from prestigious institutions including Hahnemann Medical University, Wharton School of Business, INSEAD, and the Center for Creative Leadership. During his 35-year tenure at AstraZeneca, Frank held several key positions including Executive Director of Business Development and Licensing for Cardiovascular, Metabolic and Renal Disease, Senior Director of Neuroscience Clinical Development, Managed Markets (Payer) Director, and various other leadership roles on blockbuster product such as brand leader (NEXIUM), market research director (CRESTOR, ZESTRIL), CMC team leader (SEROQUEL), and global strategic planning manager. He also served as Head of CMC Project Management and Regulatory Documentation, overseeing critical aspects of drug development. In addition, as Director of External Medical Relations Frank held strategic interface roles between key external medical/scientific/policy and governmental groups and AZ on emerging healthcare reform issues. As Managing Partner of Kondrad Consulting Group, Frank has led numerous business strategy projects for biopharmaceutical and medical device companies. His areas of focus include business development and licensing support, payer and pricing research and strategy, CMC benchmarking and regulatory readiness, brand commercialization, physician and KOL market research, and expert witness support for litigations within the pharmaceutical industry. Frank is an active member of various professional organizations including the Licensing Executive Society (LES), Academy of Managed Care Pharmacy (AMCP), American Association for the Study of Liver Diseases (AASLD), European Society of Cardiology (ESC), INTELLUS Worldwide (biopharma market research society), and is a founding member of the Pharmaceutical Section of the Project Management Institute (PMI)